07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

CBio, Inverseon deal

CBio merged with Inverseon to form newco Invion Ltd. (ASX:IVX, Brisbane, Australia). CBio issued 143.5 million to Invereson shareholders. The shares are valued at A$7.2 million ($7.4 million) based on CBio's close of A$0.05...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

CBio, Novo Nordisk deal

CBio said Novo Nordisk will not exercise its option under a May 2008 deal to negotiate an exclusive license to CBio's autoimmune product XToll ( Cpn10). The recombinant heat shock protein 10 (hsp10)...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Phase II funk

Despite the strongest public biotech financing market in a decade, companies with first-in-class lead compounds working on proof-of-concept data may continue to find it difficult to finance in 2011. Like their VC brethren, most sector...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

Chaperonin 10: Phase IIa ongoing

CBio initiated dosing of European patients in a double-blind, placebo-controlled Phase IIa trial evaluating XToll. The company plans to complete enrollment of 150 total patients in Australia, New Zealand and Europe by the end of...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

CBio, Novo Nordisk deal

CBio will receive a $1 million milestone payment from Novo Nordisk under a May 2008 deal that granted Novo an exclusive option to negotiate an exclusive license to CBio's XToll ( Cpn10). The payment...
08:00 , Feb 15, 2010 |  BioCentury  |  Finance

Small fry

Last week, one small, non-underwritten IPO made it out, while another was filed. Australian autoimmune and inflammatory disease company CBio Ltd. (ASX:CBZ) raised A$7.1 million ($6.2 million) through the sale of 7.1 million shares at A$1. The...
01:48 , Feb 9, 2010 |  BC Extra  |  Financial News

CBio raises A$7.1M in IPO

CBio Ltd. (ASX:CBZ) raised A$7.1 million ($6.2 million) through the sale of 7.1 million shares at A$1 in an IPO. The price values the company at A$75.9 million ($66 million). Novus Capital was the sponsoring...
07:00 , Oct 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Armed with two Special Protocol Agreements from FDA, Amarin Corp.(NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a second...
00:36 , Oct 13, 2009 |  BC Extra  |  Financial News

CBio raises A$10 million, planning IPO

CBio Ltd. (Brisbane, Australia) raised A$10 million ($9 million) in a venture round and unveiled plans to raise an additional A$30 million ($27 million) in an IPO this year. Novus Capital Ltd. acted as underwriter...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Clinical News

Xtoll Chaperonin 10: Phase IIa data

Data from a double-blind Phase IIa trial in 23 patients showed that the primary endpoint of DAS28 and ACR scores improved in all patients from day 14 and continued to improve at day 84. Three...